These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18351638)

  • 1. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
    Drummond DC; Noble CO; Hayes ME; Park JW; Kirpotin DB
    J Pharm Sci; 2008 Nov; 97(11):4696-740. PubMed ID: 18351638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of PEG-containing liposomal formulations on in vivo pharmacokinetics of streptokinase.
    Jin SE; Kim IS; Kim CK
    Arch Pharm Res; 2015 Oct; 38(10):1822-9. PubMed ID: 25851624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal doxorubicin.
    Tardi PG; Boman NL; Cullis PR
    J Drug Target; 1996; 4(3):129-40. PubMed ID: 8959485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
    Zucker D; Andriyanov AV; Steiner A; Raviv U; Barenholz Y
    J Control Release; 2012 Jun; 160(2):281-9. PubMed ID: 22019556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of temoporfin-loaded liposome formulations: correlation of liposome and temoporfin blood concentration.
    Decker C; Schubert H; May S; Fahr A
    J Control Release; 2013 Mar; 166(3):277-85. PubMed ID: 23313962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery.
    Eloy JO; Claro de Souza M; Petrilli R; Barcellos JP; Lee RJ; Marchetti JM
    Colloids Surf B Biointerfaces; 2014 Nov; 123():345-63. PubMed ID: 25280609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of lipid-drug conjugates loaded into liposomes.
    Signorell RD; Luciani P; Brambilla D; Leroux JC
    Eur J Pharm Biopharm; 2018 Jul; 128():188-199. PubMed ID: 29678733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting microencapsulation of drugs in liposomes.
    Kulkarni SB; Betageri GV; Singh M
    J Microencapsul; 1995; 12(3):229-46. PubMed ID: 7650588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine.
    Drummond DC; Noble CO; Guo Z; Hayes ME; Park JW; Ou CJ; Tseng YL; Hong K; Kirpotin DB
    J Pharmacol Exp Ther; 2009 Jan; 328(1):321-30. PubMed ID: 18948499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations.
    Beck-Broichsitter M; Rieger M; Reul R; Gessler T; Seeger W; Schmehl T
    Eur J Pharm Biopharm; 2013 May; 84(1):106-14. PubMed ID: 23262166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting drug release from liposomes.
    Lindner LH; Hossann M
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):111-23. PubMed ID: 20047152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopharmaceutical evaluation of the liposomes prepared by rehydration of freeze-dried empty liposomes (FDELs) with an aqueous solution of a drug.
    Yachi K; Harashima H; Kikuchi H; Sudo R; Yamauchi H; Ebihara K; Matsuo H; Funato K; Kiwada H
    Biopharm Drug Dispos; 1996 Oct; 17(7):589-605. PubMed ID: 8894117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal drug formulations in the treatment of rheumatoid arthritis.
    van den Hoven JM; Van Tomme SR; Metselaar JM; Nuijen B; Beijnen JH; Storm G
    Mol Pharm; 2011 Aug; 8(4):1002-15. PubMed ID: 21634436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal nanostructures for photosensitizer delivery.
    Jin CS; Zheng G
    Lasers Surg Med; 2011 Sep; 43(7):734-48. PubMed ID: 22057501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.
    Garg M; Asthana A; Agashe HB; Agrawal GP; Jain NK
    J Pharm Pharmacol; 2006 May; 58(5):605-16. PubMed ID: 16640829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.